2nd Mar 2015 10:31
LONDON (Alliance News) - EKF Diagnostics Holdings PLC Monday revealed an 18-month collaboration in the US that will use its PrecisionPath technology to provide genetic profiles of cancer tumours, with the aim of helping to improve treatment for colon cancer patients.
In a statement, the AIM-listed company said the move will see subsidiary Selah Genomics collaborate with US cancer institute Greenville Health Systems, DecisionQ Corp, and Becton Dickinson and Co.
"The research project is being funded in part by Becton Dickinson who have first rights to license the technology should the collaboration be a success. After the initial collaboration, a clinical trial is planned to validate the research and affirm the effectiveness of the new system as a clinical decision support tool for community based doctors," EKF said in a statement.
EKF shares were down 0.5% at 24.00 pence on Monday.
By Samuel Agini; [email protected]; @samuelagini
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Ekf Diagnostics